Exposure of Aspergillus fumigatus to stressful antifungal therapies may result in decreased susceptibility. The aim of the present work was to evaluate the susceptibility to azole and non-azole antifungals of 159 isolates of A. fumigatus collected from cystic fibrosis (CF) patients receiving azole antifungal therapy. The genetic diversity of the fungal isolates was assessed using microsatellite genotyping, and some strains were found in patient's sputum samples more than 4 years apart. No resistant isolates to antifungals appears to be rare among CF patients. However, it remains crucial to evaluate the importance of antifungal agents for allergic fungal diseases.
Introduction
Cystic fibrosis (CF) patients are continuously exposed to microorganisms that may colonise their lungs, reducing respiratory function and enhancing pulmonary problems.
Allergic bronchopulmonary aspergillosis (ABPA) is an intense allergic reaction, mainly in response to the presence of Aspergillus fumigatus, which can affect up to 15% of CF patients [1] . This allergic disease is normally treated with prescription of oral corticosteroid therapy and in a few critical clinical cases azole antifungals may be used [1, 2] .
Aspergillus fumigatus is one of the most frequently isolated fungi from the lungs of CF patients [1] . It is commonly susceptible to the commercially available antifungals such as amphotericin B, caspofungin, itraconazole, voriconazole and posaconazole [3] . It was recently showed that CF patients may be chronically colonised with the same A.
fumigatus strain over several years [4, 5] . Exposure of A. fumigatus strains to distinct conditions and stressful therapies over long periods may sporadically lead to alterations in their susceptibility and to treatment failure [6, 7] . The objective of the present work was to evaluate the susceptibility to azole and non-azole antifungals of 159 isolates of A. fumigatus collected from 11 patients, some of whom had been treated with azole antifungal therapy.
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Materials and methods

Patients
A group of 11 patients admitted to Hospital S. João (Porto, Portugal) and diagnosed with CF were studied. The diagnosis of CF was confirmed by screening CFTR mutations and positive evaluation of the sweat test. Patient age ranged from 15 years to 51 years. Patients were selected for this study following confirmation of chronic colonisation with A. fumigatus (more than three sputum samples with A. fumigatus in a previous year). Sputum samples were then collected from the patients between January 2005 and May 2009 (with a minimum of two samples from each patient at different times). Seven patients never received antifungal treatment, whilst four of the patients (patients B, C, D and E shown in Table 1 ) received azole antifungal therapy in addition to the recommended antibacterial treatment and oral corticosteroid therapy. Four of the studied patients (patients A, D, E and K shown in Table 1 ) matched with the modified criteria for diagnosis of ABPA in CF patients [2] . The patient is presently stabilised.
Antifungal therapy
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Fungal organisms
Sputum samples were cultured in Sabouraud agar for 10 days at 30 C and 37 C. A total of 159 isolates of A. fumigatus were recovered from the clinical samples. The isolates were identified based upon macroscopic and microscopic morphological characteristics following standard mycological procedures. Two A. fumigatus reference strains (ATCC 46645 and MYA 772) were included in the study. Prior to DNA isolation, moulds were grown for 5 days on Sabouraud dextrose agar slants (Difco, Detroit, MI) at 30 C. A sodium hydroxide-based method was used to extract DNA from conidia, as previously described [8] . DNA was suspended in 50 L of sterile water and stored at -20 C. A c c e p t e d M a n u s c r i p t 8 determined as previously recommended [3] . Quality control strains Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were included each time testing was performed and antifungal MICs were within the expected limits [10, 11] . Fungal strains were classified accordingly to the recently proposed in vitro breakpoints for amphotericin B, caspofungin, itraconazole and voriconazole (susceptible, MIC < 1 g/mL; intermediate, MIC = 2 g/mL; and resistant, MIC > 4 g/mL) [12] . For posaconazole, the fungal strains were classified according to recently proposed epidemiological cut-offs (wild-type, MIC < 0.25 g/mL; non-wild-type, MIC > 0.5 g/mL) [13] . Next, MICs of isolates with the same genotype were compared and were considered in essential agreement when the differences were no more than three dilutions (e.g. 0.5, 1.0 and 2.0 g/mL).
Antifungal susceptibility testing
Aspergillus fumigatus genotyping
Microsatellite multiplex polymerase chain reaction (PCR) was performed using previously selected primers allowing the identification of microsatellites based on trinucleotide, tetranucleotide and pentanucleotide motifs located on different chromosomes [8] . Multiplex PCR was performed using 1 L of genomic DNA (1-5 ng/L), 2.5 L of Multiplex PCR Master Mix (Qiagen, Hilden, Germany) and 0.5 L of a mix with eight primer pairs (final concentration of each primer 2 M) in a final volume of 5 L. The conditions for PCR amplification and sequencing reactions were as previously described [8] .
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Statistical analysis
Data were compared at a significance level of 0.05 by analysis of variance (ANOVA) using the Bonferroni correction, and Student's t-test for paired samples. Genotype diversity was calculated by Simpson's index of diversity. Statistical analysis for pair-wise linkage disequilibrium was performed by running the statistical software package Arlequin 3.1 (http://cmpg.unibe.ch/software/arlequin3/).
Results
Among the entire A. fumigatus collection, no resistant isolates (MIC/MEC ≥ 4 g/mL) were identified to the antifungals amphotericin B, caspofungin, itraconazole and voriconazole ( Table 1 ). The susceptibility of a few isolates was classified as intermediate to amphotericin B (3 isolates) and itraconazole (18 isolates), and a single A. fumigatus isolate was identified outside of the epidemiological cut-off of 0.25 g/mL for posaconazole (this last isolate showed a susceptibility of 0.5 g/mL for amphotericin B, 0.06 g/mL for caspofungin, 2 g/mL for itraconazole and 0.5 g/mL for voriconazole). The number of isolates with intermediate susceptibility to itraconazole collected from patients was similar before and after azole treatment (P > 0.05).
The genotype diversity of A. fumigatus found in each patient's sample collection ranged from 0.6 to 1, with an overall diversity of 0.92 when considering the entire group of 159
isolates. There was no significant relationship between A. fumigatus genotype diversity and the patient's diagnosis of ABPA (P > 0.05). Some strains were frequently found in M a n u s c r i p t 10 the sputum samples of patients, occasionally more than 4 years apart. A total of 15 strains were repeatedly recovered from the clinical samples (total of 134 isolates) and the susceptibility of the repeated isolates (with the same genotype for all eight microsatellite markers) was in agreement with the susceptibility of the isolate that was first identified (100% essential agreement). Eight of the recurrent (or chronic) strains of A. fumigatus had been exposed to an azole antifungal. Even after azole exposure, some recurrent A. fumigatus (four strains) were still detected in the subsequent sputum samples collected from the patients. Patient B was colonised with three of these recurrent strains and no significant differences were found between the susceptibility of the strains before and after exposure to itraconazole and voriconazole (P > 0.05).
Microvariation events were common among the clinical A. fumigatus isolates collected from six of the patients included in the study; three patients were diagnosed with ABPA.
These events were more common between isolates recovered from the same sputum sample (e.g. events 4, 5 or 8), but they could be found in two samples from the same patient collected with more than 3 years apart.
Discussion
Oral corticosteroid therapy remains the first therapy for ABPA and there is still no consensus regarding how, how long or when antifungal drugs should be employed for treatment of patients with ABPA or those colonised with Aspergillus spp. [2, 14] . Patients included in this study received azole antifungal therapy due to serious haemoptysis Page 11 of 17 A c c e p t e d M a n u s c r i p t 11 and/or decrease of respiratory function and clinical deterioration following administration of antibacterial treatment and/or corticosteroid therapy. In all cases there was verified clinical progress and favourable outcome. Antifungals have been seldom used for therapy among CF patients, but the long-standing and significant adverse effects of corticosteroid therapy, the difficulties associated with a firm diagnosis of ABPA and the clinical deterioration of chronically ill patients may result in the near future in an increase of antifungal usage among CF patients [14] .
During the last decade there has been an increase, although infrequent, in the description of itraconazole resistance among A. fumigatus isolates obtained from patients with invasive fungal infections receiving antifungal drugs [6, 13] . Resistance to voriconazole or posaconazole has been more rarely reported. Recently, the association of A. fumigatus azole resistance in allergic diseases was described resulting from prior exposure to an antifungal azole agent [7] . In all cases, treatment failure was reported and several A. fumigatus strains were identified as resistant to itraconazole, voriconazole and/or posaconazole. Conversely, in this study we could not detect any resistant A. fumigatus isolate to the five tested antifungals, azoles or non-azoles (a few fungal isolates were intermediate to amphotericin B or itraconazole). Nevertheless, we did not find unfavourable outcomes among the 11 evaluated patients.
Microsatellite genotyping results demonstrated that cystic CF fibrosis patients may be chronically colonised with the same strains, sometimes over several years as previously described [4, 5] . In any case, exposure to an antifungal azole did not reduce the M a n u s c r i p t 12 susceptibility of A. fumigatus genotypes chronically recovered from patients and, occasionally, among isolates that showed microvariation (disparity in a single marker).
However, we can question whether the use of azole antifungal therapy was really effective. One-half of the recurrent A. fumigatus strains were detected in the subsequent sputum samples collected from patients. The limited number of studied patients and, in particular, the fact that all patients showed a good response to the therapy may limit additional conclusions. Nevertheless, we can assume with the present results that azole antifungal resistance is not a common event among A. fumigatus isolates collected from CF patients. Aspergillus fumigatus isolates may become resistant to antifungals only under particular conditions, uncommon therapeutic options and/or unusual structures.
An example is mould biofilm that may be present in the CF lung and has already been 
